Physician profile
Peter Eugene Libre
NPI 1013013671
$2,486.97
in general payments reported to CMS, 2019-2025
11 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2022: $243 · 2023: $895 · 2024: $402 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,003.62 | 2022-2025 | |
| Glaukos Corporation | $536.30 | 2023 | |
| Allergan, INC. | $301.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.21 | 2023-2025 | Entyvio |
| Sight Sciences, INC. | $144.87 | 2022-2023 | Omni Surgical System |
| New World Medical,INC. | $140.31 | 2025 | Via360, Clearpath, Streamline |
| Harrow Eye, LLC | $76.05 | 2024-2025 | |
| Halozyme INC | $31.20 | 2024 | Hylenex Recombinant |
| Rxsight INC | $24.71 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Janssen Biotech, INC. | $20.68 | 2024 | Tremfya, Stelara, Simponi Aria |
| Alcon Vision LLC | $16.57 | 2023 | Hydrus Microstent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Libre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.